A 3-part, Phase 1a/1b, First-in-human, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Oral CDX-7108 in Healthy Adult Subjects and to Evaluate Proof-of-concept Via Pharmacodynamics of a Single Dose of Oral CDX-7108 in Subjects With Exocrine Pancreatic Insufficiency
Latest Information Update: 28 Apr 2023
At a glance
- Drugs CDX-7108 (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Nestle
- 24 Apr 2023 Status changed from recruiting to completed.
- 23 Feb 2023 According to Codexis media release, the company aims for the potential initiation of a phase II study in early 2024.
- 23 Feb 2023 Interim results published in the Codexis media release.